Ainos Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Chun-Hsien Tsai

Algemeen directeur

US$916.0k

Totale compensatie

Percentage CEO-salaris	20.31%
Dienstverband CEO	5.2yrs
Eigendom CEO	5.6%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5.2yrs

Recente managementupdates

Recent updates

Analyseartikel • Dec 12

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Ainos (NASDAQ:AIMD) has surged 50% premarket after the company said its low-dose oral interferon (IFN)-alpha formulation Veldona showed a positive effect on lungs infected with the the Omicron variant of the coronavirus by regulating the immune response, thereby expediting recovery of hamsters. The copany had filed an application to the U.S. Food and Drug Administration (FDA) seeking clearance to conduct a phase 2 trial for the drug. The study tested the effectiveness of Veldona over a sixteen-day course and compared with hamsters in the placebo group. The hamsters in the group receiving Veldona showed resistance to body weight loss immediately after infection, then showed a better recovery trend in the following three days.

Seeking Alpha • Aug 24

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Ainos (NASDAQ:AIMD) filed an application to the U.S. Food and Drug Administration (FDA) seeking clearance to conduct a phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation Veldona to treat mild symptoms related to COVID-19. Earlier in August, the company said that it had started a phase 2 trial of Veldona in patients with mild COVID-19 in Taiwan, following results from preclinical studies. "Our Company is investigating whether impaired type I IFN could be related to persistent high blood viral loads and inflammatory responses in COVID-19 cases," said Chairman President and CEO Chun-Hsien Tsai. AIMD +5.28% to $2.59 premarket Aug. 24

Seeking Alpha • Aug 15

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Amarillo Biosciences press release (NASDAQ:AIMD): Q2 GAAP EPS of -$0.01. Revenue of $636.62M (+213.6% Y/Y).

Analyse CEO-vergoeding

Hoe is Chun-Hsien Tsai's beloning veranderd ten opzichte van Ainos's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2026	n/a	n/a	-US$14m
Dec 31 2025	US$916k	US$186k	-US$15m
Sep 30 2025	n/a	n/a	-US$15m
Jun 30 2025	n/a	n/a	-US$16m
Mar 31 2025	n/a	n/a	-US$15m
Dec 31 2024	US$302k	US$123k	-US$15m
Sep 30 2024	n/a	n/a	-US$16m
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$1m	US$96k	-US$14m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$15m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$4m	US$100k	-US$14m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$7m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$82k	US$45k	-US$4m

Compensatie versus markt: De totale vergoeding ($USD 916.01K ) Chun-Hsien } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 642.98K ).

Compensatie versus inkomsten: De vergoeding van Chun-Hsien is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chun-Hsien Tsai (56 yo)

5.2yrs

Tenure

US$916,008

Compensatie

Mr. Chun-Hsien Tsai has been Chairman of Board, President and Chief Executive Officer at Ainos, Inc. since April 15, 2021 and served as its Chief Financial Officer since April 15, 2021 until August 11, 202...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Chun-Hsien Tsai	CEO, President & Chairman of the Board	5.2yrs	US$916.01k	5.57% $ 783.8k
Yao-Chung Chiang	Independent Director	5.2yrs	US$194.80k	0.15% $ 21.5k
Pao-Sheng Wei	Independent Director	4yrs	US$200.80k	1.23% $ 173.6k
Wen-Han Chang	Independent Director	5.2yrs	US$199.30k	1.38% $ 194.0k
Ting-Chuan Lee	Director	5.2yrs	US$699.03k	10.96% $ 1.5m
Chun-Jung Tsai	Director	5.2yrs	US$699.03k	8.94% $ 1.3m
Chung-Yi Tsai	Director	5.2yrs	US$190.80k	1.23% $ 173.6k

5.2yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AIMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/14 17:37
Aandelenkoers aan het einde van de dag	2026/06/12 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Ainos, Inc. wordt gevolgd door 0 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Ainos Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Director recently sold US$209k worth of stock

Ainos, Inc., Annual General Meeting, Nov 07, 2025

Ainos, Inc., Annual General Meeting, Sep 27, 2024

Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary

Less than half of directors are independent

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Recent updates

Director recently sold US$209k worth of stock

First quarter 2026 earnings released: US$0.41 loss per share (vs US$1.04 loss in 1Q 2025)

New major risk - Market cap size

Ainos (NASDAQ:AIMD) Has Debt But No Earnings; Should You Worry?

New major risk - Market cap size

Ainos, Inc., Annual General Meeting, Nov 07, 2025

Ainos (NASDAQ:AIMD) Is Carrying A Fair Bit Of Debt

First quarter 2025 earnings released: US$0.21 loss per share (vs US$0.57 loss in 1Q 2024)

Full year 2024 earnings released: US$1.56 loss per share (vs US$3.36 loss in FY 2023)

Ainos, Inc. Announces Institutional Review Board Approval for Sjögren’S Syndrome Clinical Study

Third quarter 2024 earnings released: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023)

Ainos, Inc. Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for HIV-Oral Warts Clinical Trial

Ainos Announces Plan to Initiate Taiwan Clinical Study for Veldona as Potential Treatment of Oral Warts in HIV-Positive Patients

Ainos, Inc. Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Ainos, Inc., Annual General Meeting, Sep 27, 2024

Second quarter 2024 earnings released: US$0.49 loss per share (vs US$0.58 loss in 2Q 2023)

Ainos, Inc Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.63 loss in 1Q 2023)

New major risk - Shareholder dilution

We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

Full year 2023 earnings released: US$3.36 loss per share (vs US$5.14 loss in FY 2022)

Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms

New minor risk - Shareholder dilution

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell

Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary

Less than half of directors are independent

Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.20 loss in 2Q 2022)

Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price Requirement

Ainos, Inc. Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20 Million Revenue Target

Ainos, Inc. Announces Chief Financial Officer Changes

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2022)

Full year 2022 earnings released: US$1.03 loss per share (vs US$0.52 loss in FY 2021)

Ainos Receives Non-Compliance Notice From Nasdaq

Ainos, Inc Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals

Third quarter 2022 earnings released: US$0.51 loss per share (vs US$0.12 loss in 3Q 2021)

Less than half of directors are independent

Ainos, Inc. Pursues Licensing Partners to Accelerate Five Candidates of Its Low-Dose Oral Interferon Formulation Veldona to Phase 3 Trials and Commercialization

Ainos Announces Positive Results from Additional Preclinical Study of Its Low-Dose Oral Interferon Formulation Against New Variant Virus - Omicron

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Second quarter 2022 earnings released: US$0.014 loss per share (vs US$0.09 loss in 2Q 2021)

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Ainos, Inc. has completed a Composite Units Offering in the amount of $3.315 million.

Less than half of directors are independent

Ainos Announces Positive Results from Preclinical Studies of Its Low-Dose Oral Interferon Formulation Against Covid-19

Ainos, Inc. Announces Executive Changes

Ainos, Inc. announced delayed 10-Q filing

Analyse CEO-vergoeding

CEO

Bestuursleden

Bedrijfsanalyse en status van financiële gegevens

Gegevensbronnen

Analysemodel en Snowflake

Industrie en sector

Bronnen van analisten